Современные подходы к лечению мышечно-инвазивного рака мочевого пузыря


DOI: https://dx.doi.org/10.18565/pharmateca.2022.7.49-52

Хэ Минцзэ, Цзен Цзытун

Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет), Москва, Россия
Рак мочевого пузыря (РМП) является одним из наиболее распространенных злокачественных новообразований в урологии. В последнее время подходы к лечению мышечно-инвазивного РМП претерпели значительные изменения: от радикальной цистэктомии до комбинированного лечения с сохранением мочевого пузыря; от открытого хирургического вмешательства до эндоскопического минимально инвазивного вмешательства и робот-ассоциированной хирургии. В данной статье приведен обзор современных методов лечения мышечно-инвазивного РМП.

Литература


1. Lazaro M., Gallardo E., Domenech M., et al. SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer. Clin Transl Oncol. 2016;18(12):1197–205. doi: 10.1007/s12094-016-1584-z. Erratum in: Clin Transl Oncol. 2019;21(6):817. Del Alba AG


2. Milowsky M.I., Rumble R.B., Booth C.M., et al. Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2016;34(16):1945–52. Doi: 10.1200/ JCO.2015.65.9797.


3. De Nunzio C.L., Leonardo C., et al. Analysis of radical cystectomy and urinary diversion complications with the Clavien classification system in an Italian real life cohort. Eur J Surg Oncol. 2013;39(7):792–98. Doi: 10.1016/j. ejso.2013.03.008.


4. Gakis G., Efstathiou J., Lerner S.P., et al. International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013;63(1):45–57. Doi: 10.1016/j. eururo.2012.08.009.


5. Capitanio U., Isbarn H., Shariat S.F., et al. Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysist. Urology. 2009;74(4):858– 64. Doi: 10.1016/j.urology.2009.03.052.


6. Chang S., Benson M., Fukui I. Muscle-invasive urothelial carcinoma of the bladder. Urology. 200;69(Suppl. 1):3–16. Doi: 10.1016/j. urology.2006.10.040.


7. Tyson M.D., Barocas D.A. Quality of Life After Radical Cystectomy. Urol Clin North Am. 2018;45(2):249–56. doi: 10.1016/j. ucl.2017.12.008.


8. Siracusano S., D’Elia C., Cerruto M.A., et al. Quality of life following urinary diversion: Orthotopic ileal neobladder versus ileal conduit. A multicentre study among long-term, female bladder cancer survivors. Eur J Surg Oncol. 2019;45(3):477–81. Doi: 10.1016/j.ejso.2018.10.061.


9. Kang S.G., Ko Y.H., Jang H.A., et al. Initial experience of robot-assisted radical cystectomy with total intracorporeal urinary diversion: comparison with extracorporeal method. J Laparoendosc Adv Surg Tech A. 2012;22(5):456– 62. Doi: 10.1089/lap.2011.0249.


10. McKenzie P.L., Hemal A.K. Surgeon controlled robot-assisted laparoscopic radical cystectomy: current review of oncologic and functional outcomes. Minerva Urol Nefrol. 2012;64(2):79–88.


11. Pham A., Ballas L.K. Trimodality therapy for bladder cancer: modern management and future directions. Curr Opin Urol. 2019;29(3):210–15. Doi: 10.1097/MOU.0000000000000601.


12. Kulkarni G.S., Hermanns T., Wei Y., et al. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. J Clin Oncol. 2017;35(20):2299–305. Doi: 10.1200/ JCO.2016.69.2327.


13. Vashistha V., Wang H., Mazzone A., et al. Radical Cystectomy Compared to Combined Modality Treatment for Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Int J Radiat Oncol Biol Phys. 2017;97(5):1002–20. Doi: 10.1016/j.ijrobp.2016.11.056.


14. Herr H.W., Dotan Z., Donat S.M., Bajorin D.F. Defining optimal therapy for muscle invasive bladder cancer. J Urol. 2007;177(2):437–43. Doi: 10.1016/j.juro.2006.09.027.


15. Grossman H.B., Natale R.B., Tangen C.M., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66. Doi: 10.1056/NEJMoa022148. Erratum in: N Engl J Med. 20036;349(19):1880.


16. International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group, Griffiths G., Hall R., Sylvester R., Raghavan D., Parmar M.K. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011; 29(16):2171–77. Doi: 10.1200/JCO.2010. 32.3139.


17. Bateni Z.H., Pearce S.M., Zainfeld D., et al. National Practice Patterns and Overall Survival After Adjuvant Radiotherapy Following Radical Cystectomy for Urothelial Bladder Cancer in the USA, 2004-2013. Eur Urol Oncol. 2020;3(3):343–50. Doi: 10.1016/j.euo.2018.11.010.


18. Boorjian S.A., Sheinin Y., Crispen P.L., et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res. 2008;14(15):4800–808. Doi: 10.1158/1078-0432.CCR-08-0731.


19. Walshaw R.C., Honeychurch J., Illidge T.M., Choudhury A. The anti-PD-1 era – an opportunity to enhance radiotherapy for patients with bladder cancer. Nat. Rev. Urol. 2018;15(4):251–59. Doi: 10.1038/nrurol.2017.172.


Об авторах / Для корреспонденции


Автор для связи: Хэ Минцзэ, аспирант кафедры урологии, Первый МГМУ им. И.М. Сеченова (Сеченовский Университет), Москва, Россия; hemingze1997@gmail.com


ORCID:
Хэ Минцзэ (He Mingze), https://orcid.org/0000-0003-0601-4713
Цзен Цзытун (Zeng Zitong), https://orcid.org/0000-0001-9312-486X


Похожие статьи


Бионика Медиа